Loss of MutL disrupts Chk2-dependent cell cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer

Significant endocrine therapy-resistant tumor proliferation is present in ≥20% of estrogen receptor positive (ER(+)) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismat...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Discov
Κύριοι συγγραφείς: Haricharan, Svasti, Punturi, Nindo, Singh, Purba, Holloway, Kimberly R., Anurag, Meenakshi, Schmelz, Jacob, Schmidt, Cheryl, Lei, Jonathan T., Suman, Vera, Hunt, Kelly, Olson, John A., Hoog, Jeremy, Li, Shunqiang, Huang, Shixia, Edwards, Dean P., Kavuri, Shyam M., Bainbridge, Matthew N., Ma, Cynthia X., Ellis, Matthew J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5733075/
https://ncbi.nlm.nih.gov/pubmed/28801307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1179
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια